Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.12.2024 | editorial

KRAS: Finally a druggable target in oncology?

verfasst von: Aysegul Ilhan-Mutlu, MD, PhD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Auszug

After the initial establishment of microsatellite instability (MSI) as a tissue-agnostic biomarker, medical oncology is increasingly faced with other biomarkers that are assessed beyond tumor tissue type and have appropriate treatment options [1]. Although Kirsten rat sarcoma viral oncogene homologue (KRAS) was discovered as one of the first oncogenes, direct inhibition of the KRAS molecule has not yet been possible. Evaluating KRAS status helped us to implement upstream or downstream inhibitor molecules as this was considered a predictive biomarker [2]. …
Nächster Artikel Not only a chicken and egg problem in children with pancytopenia
Literatur
1.
Gouda MA, Nelson BE, Buschhorn L, Wahida A, Subbiah V. Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications. Clin. Cancer Res. 2023;29(15):2753–60.
2.
Garcia-Carbonero N, Martinez-Useros J, Li W, Orta A, Perez N, Carames C, et al. KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study. Cells. 2020;9(1).
3.
4.
Schmitz K, Schatz C, Knabl L. KRAS in modern oncology – The Molecular Pathological point of view. memo. 2024;.
5.
Unraveling DB. (K)RAS in pancreatic ductal adenocarcinoma. memo. 2024;.
Metadaten
Titel
KRAS: Finally a druggable target in oncology?
verfasst von
Aysegul Ilhan-Mutlu, MD, PhD
Publikationsdatum
01.12.2024
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2024
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-024-01004-5

Weitere Artikel der Ausgabe 4/2024

NEC versus NET G3—is there a grey zone? Case report of pancreatic NET G3 with rapid disease progression

  • Open Access
  • case report

Importance of genetic clarification in cytopenia syndromes (childhood myelodysplastic syndrome forms)

  • Open Access
  • case report

Unraveling (K)RAS in pancreatic ductal adenocarcinoma

  • Open Access
  • short review

GATA2 deficiency: a mystery myelodysplasia

  • Open Access
  • case report

CAR-T cell therapy for relapsed or refractory multiple myeloma in 2024—clinically available treatment options in Austria

  • short review

Next generation of drugs in breast cancer

  • Open Access
  • short review